ClinicalTrials.gg
Drug

Relugolix clinical trials

Also written TAK-385, Orgovyx and MVT-601.

studies test it
45
open now
13
in phase 3
18
first study started
2011

How each study uses relugolix is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the relugolix studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
18 Dec 2020 · ORGOVYX · NDA 214621 (FDA, Drugs@FDA)
European Union
16 Jul 2021 · Ryeqo · EMEA/H/C/005267 (EMA; in a combination)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Relugolix
28
N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea
7
Relumina
7
T-1331285
3
Myfembree
3

Brand

Orgovyx
13

Development codes

TAK-385
30
MVT-601
10
RVT-601
4

Studies by the year they started

45 studies that test it; most in 2024 (11)

Studies that test relugolix, by start year
YearStudies
20112
20121
20145
20151
20164
20176
20182
20191
20213
20222
20233
202411
20253
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
9
Phase 2
17
Phase 3
18

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 27 · Other 18

Myovant Sciences GmbH (10) · Takeda (9) · Millennium Pharmaceuticals, Inc. (3) · NRG Oncology (2) · Emory University (2) · Sumitomo Pharma Switzerland GmbH (2) · AdventHealth (1) · Atish Choudhury, MD (1)

Often tested with

Tested in the same studies.

Leuprolide (5) · Darolutamide (3) · Bicalutamide (2) · Degarelix (2) · Triptorelin (2) · Estradiol (2) · Enzalutamide (2) · Buserelin (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 2 in phase 3

Studies that test relugolix, phase 3 first.

Studies

Open first, then newest update. How each study uses relugolix is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 45

See all 45 studies that test relugolix →

Given beside what is tested · 5 — relugolix is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with relugolix

Codes

What other systems call relugolix · ClinicalTrials.gg INT005900

  • MeSH (NLM) C561634relugolixOne source ClinicalTrials.gov
  • UNII (FDA) P76B05O5V6RELUGOLIXConfirmed FDA, Wikidata
  • RxNorm 2472778One source FDA
  • Wikidata Q21099000relugolixConfirmed FDA, Wikidata
  • NCI Thesaurus C114498RelugolixOne source FDA
  • DrugBank DB11853One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.